Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura A Williams

Showing results (11-20 of 32) with videos related to

Pageof 4
Sort By:
Journal of Women'S Health (2002)|February 4, 2021
The Patient Experience of Premenopausal Women Treated with Bremelanotide for Hypoactive Sexual Desire Disorder: RECONNECT Exit Study ResultsPatricia Koochaki, Dennis Revicki, Hilary Wilson, et al.
Obstetrics and Gynecology|October 11, 2019
Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 TrialsSheryl A Kingsberg, Anita H Clayton, David Portman, et al.
Cardiovascular Drugs and Therapy|December 22, 2010
Achievement of lipid targets with the combination of rosuvastatin and fenofibric Acid in patients with type 2 diabetes mellitusRobert S Rosenson, Dawn M Carlson, Maureen T Kelly, et al.
Obstetrics and Gynecology|October 11, 2019
Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire DisorderJames A Simon, Sheryl A Kingsberg, David Portman, et al.
Journal of Clinical Pharmacology|September 24, 2011
Exposure-clinical response analysis of paricalcitol in patients with chronic kidney disease (stage 5) on hemodialysis or peritoneal dialysisPeter A Noertersheuser, Rajendra S Pradhan, Cheri E Klein, et al.
Nephron. Clinical Practice|March 15, 2006
The effect of hepatic insufficiency on the safety and pharmacokinetics of paricalcitol (Zemplar)Robert A Carr, Amy K André, Ping Chen, et al.
Clinical Therapeutics|July 30, 2013
A randomized, double-blind study of fenofibric acid plus rosuvastatin compared with rosuvastatin alone in stage 3 chronic kidney diseaseDebra L Weinstein, Laura A Williams, Dawn M Carlson, et al.
Clinical Cardiology|October 21, 2010
Combination rosuvastatin plus fenofibric acid in a cohort of patients 65 years or older with mixed dyslipidemia: subanalysis of two randomized, controlled studiesCarl J Pepine, Terry A Jacobson, Dawn M Carlson, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|May 30, 2007
Intravenous paricalcitol for treatment of secondary hyperparathyroidism in children on hemodialysisLarry A Greenbaum, Nadine Benador, Stuart L Goldstein, et al.
Pediatric Nephrology (Berlin, Germany)|March 24, 2005
Intravenous calcitriol for treatment of hyperparathyroidism in children on hemodialysisLarry A Greenbaum, Ryszard Grenda, Ping Qiu, et al.
Pageof 4

Showing results (11-20 of 32) with videos related to

Sort By:
Pageof 4
Journal of Women'S Health (2002)|February 4, 2021
The Patient Experience of Premenopausal Women Treated with Bremelanotide for Hypoactive Sexual Desire Disorder: RECONNECT Exit Study ResultsPatricia Koochaki, Dennis Revicki, Hilary Wilson, et al.
Obstetrics and Gynecology|October 11, 2019
Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 TrialsSheryl A Kingsberg, Anita H Clayton, David Portman, et al.
Cardiovascular Drugs and Therapy|December 22, 2010
Achievement of lipid targets with the combination of rosuvastatin and fenofibric Acid in patients with type 2 diabetes mellitusRobert S Rosenson, Dawn M Carlson, Maureen T Kelly, et al.
Obstetrics and Gynecology|October 11, 2019
Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire DisorderJames A Simon, Sheryl A Kingsberg, David Portman, et al.
Journal of Clinical Pharmacology|September 24, 2011
Exposure-clinical response analysis of paricalcitol in patients with chronic kidney disease (stage 5) on hemodialysis or peritoneal dialysisPeter A Noertersheuser, Rajendra S Pradhan, Cheri E Klein, et al.
Nephron. Clinical Practice|March 15, 2006
The effect of hepatic insufficiency on the safety and pharmacokinetics of paricalcitol (Zemplar)Robert A Carr, Amy K André, Ping Chen, et al.
Clinical Therapeutics|July 30, 2013
A randomized, double-blind study of fenofibric acid plus rosuvastatin compared with rosuvastatin alone in stage 3 chronic kidney diseaseDebra L Weinstein, Laura A Williams, Dawn M Carlson, et al.
Clinical Cardiology|October 21, 2010
Combination rosuvastatin plus fenofibric acid in a cohort of patients 65 years or older with mixed dyslipidemia: subanalysis of two randomized, controlled studiesCarl J Pepine, Terry A Jacobson, Dawn M Carlson, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|May 30, 2007
Intravenous paricalcitol for treatment of secondary hyperparathyroidism in children on hemodialysisLarry A Greenbaum, Nadine Benador, Stuart L Goldstein, et al.
Pediatric Nephrology (Berlin, Germany)|March 24, 2005
Intravenous calcitriol for treatment of hyperparathyroidism in children on hemodialysisLarry A Greenbaum, Ryszard Grenda, Ping Qiu, et al.
Pageof 4